醫學系

Medicine & Life Sciences

1. Taiwan 100%
2. Neoplasms 30%
3. Population 28%
4. Cohort Studies 27%
5. Stroke 25%
6. Meta-Analysis 25%
7. Therapeutics 24%
8. Apoptosis 23%
9. Confidence Intervals 22%
10. Systematic Reviews 16%
11. Proteins 16%
12. Randomized Controlled Trials 15%
13. Odds Ratio 15%
14. Wounds and Injuries 15%
15. Mortality 14%
16. Hepatocellular Carcinoma 14%
17. Lung 13%
18. Neoplasm Metastasis 13%
19. Genes 13%
20. In Vitro Techniques 13%
21. Breast Neoplasms 13%
22. Arsenic 13%
23. Kidney 12%
24. Databases 12%
25. Chronic Renal Insufficiency 12%
26. Serum 12%
27. Colorectal Neoplasms 12%
28. Inflammation 12%
29. Autophagy 11%
30. Incidence 11%
31. Lipopolysaccharides 11%
32. Reactive Oxygen Species 11%
33. Down-Regulation 11%
34. Survival 10%
35. National Health Programs 10%
36. Pharmaceutical Preparations 10%
37. Growth 10%
38. Phosphorylation 10%
39. Endothelial Cells 10%
40. Macrophages 9%
41. Brain 9%
42. Blood Platelets 9%
43. Biomarkers 9%
44. Oxidative Stress 9%
45. Retrospective Studies 9%
46. Carcinoma 8%
47. Liver 8%
48. Traumatic Brain Injury 8%
49. Atrial Fibrillation 8%
50. Nitric Oxide 8%
51. Up-Regulation 8%
52. Renal Dialysis 8%
53. Lung Neoplasms 8%
54. Gene Expression 8%
55. MicroRNAs 8%
56. Elderly 8%
57. Child 8%
58. Metabolic Syndrome 8%
59. Glucose 8%
60. Antioxidants 8%
61. Prostatic Neoplasms 8%
62. Recurrence 8%
63. Cytokines 8%
64. Bipolar Disorder 8%
65. Glioblastoma 8%
66. Cardiac Myocytes 7%
67. Pain 7%
68. Nanoparticles 7%
69. Heme Oxygenase-1 7%
70. Hypertension 7%
71. Infections 7%
72. Cell Proliferation 7%
73. Blood Pressure 7%
74. Messenger RNA 7%
75. Bone and Bones 7%
76. Schizophrenia 7%
77. Parkinson Disease 7%
78. Cell Movement 7%
79. Control Groups 7%
80. Drug Therapy 7%
81. Calcium 7%
82. Tuberculosis 7%
83. Type 2 Diabetes Mellitus 7%
84. Fibrosis 7%
85. Skin 7%
86. Non-Small Cell Lung Carcinoma 7%
87. Logistic Models 6%
88. Dementia 6%
89. Magnetic Resonance Imaging 6%
90. Cell Line 6%
91. Colonic Neoplasms 6%
92. Exercise 6%
93. Safety 6%
94. Case-Control Studies 6%
95. Quality of Life 6%
96. ErbB Receptors 6%
97. Sepsis 6%
98. Pulmonary Veins 6%
99. Cell Death 6%
100. Catenins 6%